TY - JOUR
AR - ACO-2018-1-104
TI - Diminishing oncometabolic havoc: Approved IDH1 and IDH2 inhibitors in relapsed or refractory acute myeloid leukemia
AU - Jun , Gong
JO - Annals of Clinical Oncology
PY - 2018
DA - Fri 28, Dec 2018
SN - 2674-3248
DO - http://dx.doi.org/10.31487/j.ACO.2018.01.004
UR - https://www.sciencerepository.org/diminishing-oncometabolic-havoc-approved-idh1-and-idh2-inhibitors-in-relapsed-or-refractory-acute-myeloid-leukemia_ACO-1-104 
KW - Isocitrate dehydrogenase inhibitor, acute myeloid leukemia,  somatic mutation,  relapsed or refractory,  differentiation syndrome
AB - Activating somatic mutations in isocitrate dehydrogenase (IDH) isoforms 1 and 2 in acute myeloid leukemia
(AML) have been shown to contribute in wreaking intracellular oncometabolic havoc that adversely affects
cellular growth and differentiation. Novel developments in IDH1 and IDH2 inhibitors have led to the recent
U.S. Food and Drug Administration (FDA) approvals of these targeted agents in relapsed or refractory AML
harboring these respective driver mutations. Their promising efficacy and well-tolerated toxicity profiles
render them welcomed additions in the treatment landscape of AML. However, the IDH1 and IDH2
inhibitors ivosidenib and enasidenib, respectively, have unique class-effect toxicities that warrant early
recognition in order for prompt management and re-institution of an otherwise effective class of agents.